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The high level of 5-hydroxymethylcytosine (5hmC)
present in neuronal genomes suggests that mecha-
nisms interpreting 5hmC in the CNS may differ
from those present in embryonic stem cells. Here,
we present quantitative, genome-wide analysis of
5hmC, 5-methylcytosine (5mC), and gene expression
in differentiated CNS cell types in vivo.We report that
5hmC is enriched in active genes and that, surpris-
ingly, strong depletion of 5mC is observed over these
regions. The contribution of these epigenetic marks
to gene expression depends critically on cell type.
We identify methyl-CpG-binding protein 2 (MeCP2)
as the major 5hmC-binding protein in the brain
and demonstrate that MeCP2 binds 5hmC- and
5mC-containing DNA with similar high affinities. The
Rett-syndrome-causing mutation R133C preferen-
tially inhibits 5hmC binding. These findings support
a model in which 5hmC and MeCP2 constitute
a cell-specific epigenetic mechanism for regulation
of chromatin structure and gene expression.
INTRODUCTION
The appearance of the nucleus and the architecture of chromatin
vary substantially in terminally differentiated central nervous
system (CNS) cell types (Palay and Chan-Palay, 1974). The
recent discovery of 5-hydroxymethylcytosine (5hmC) in the
mammalian genome and the demonstration that it is approxi-
mately 10-fold more abundant in neurons than in some periph-
eral tissues or embryonic stem (ES) cells (Kriaucionis and Heintz,
2009; Mu¨nzel et al., 2010; Szulwach et al., 2011) suggests that
5hmC is a stable epigenetic mark that engages cell-specific
mechanisms to carry out its functions in the brain. Consistent
with this view, recent studies mapping the genomic distribution
of 5hmC in the hippocampus and cerebellum have established
that the distribution of 5hmC varies between brain areas, andCthat the location of 5hmC in the genome differs significantly
between the brain and ES cells (Szulwach et al., 2011). For
example, 5hmC is present preferentially in specific classes of
promoter and enhancer elements that regulate the pluripotent
state in ES cells (Pastor et al., 2011; Yu et al., 2012; Booth
et al., 2012), whereas in the brain it is enriched in gene bodies
and depleted from transcription start sites (TSS) (Szulwach
et al., 2011). To understand the importance of these distinctions,
and to determine whether the mechanisms that decode
cytosine methylation status are cell and tissue specific, we
have pursued two strategies in parallel: quantitative, genome-
wide, cell-specific measurements of gene expression and
genomic cytosine modification in defined CNS cell types; and
biochemical analysis of proteins involved in 5hmC binding in
the nervous system.
We have chosen for these studies two classically defined
neuronal cell types, Purkinje cells (PCs) and granule cells
(GCs), and the terminally differentiated and specialized Berg-
mann glial (BG) cell population that is coresident with them in
the cerebellum. PCs are among the largest cells in the brain.
PC nuclei are large and pale, and themajority of heterochromatin
detectable at the ultrastructural level is present surrounding the
large, centrally located nucleolus (Palay and Chan-Palay, 1974).
GCs are the smallest and most numerous neurons of the cere-
bellum, present at several hundred times the abundance of
PCs (Palay and Chan-Palay, 1974; Lange, 1975). GC nuclei are
small, compact, and contain large blocks of condensed hetero-
chromatin localized in nuclear periphery. BG, originally referred
to as Golgi epithelial cells (Palay and Chan-Palay, 1974), have
a radial morphology that distinguishes them from the much
more abundant, typical protoplasmic astrocytes. BG nuclei are
intermediate in size and structure between PC and GC nuclei,
and contain a few small, dense clumps of heterochromatin.
The distinctive structures of these three neural cell types
suggests that their analysis can provide important insights into
cell-specific relationships between genomic cytosine modifica-
tion and nuclear function.
We demonstrate here that the relationship among the genomic
distribution of 5hmC, the genomic distribution of 5-methylcyto-
sine (5mC), and gene expression is cell specific. We identifyell 151, 1417–1430, December 21, 2012 ª2012 Elsevier Inc. 1417
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Figure 1. Cell-Type-Specific Gene Expression in Cerebellar Cell Types by TRAP-Seq
(A) Visualization of FPKM values of TRAP-seq data of various examples in PCs, GCs, and BG. Pcp4 and Pvalb are enriched in PCs (blue), Neurod2 and Calb2 are
enriched inGCs (orange), andGstm1 andGfap are enriched in BG (green). Values of RNA sequencing for these genes from total cerebellum (black) are also shown
for comparison. Scale (minimum-maximum) is indicated on the top left corner of PC line for each gene. Windows show the following locations: Pcp4
chr16:96,683,159-96,757,502; Pvalb chr15:78,019,548-78,036,586; Neurod2 chr11:98,186,324-98,191,364; Calb2 chr8:112,663,312-112,696,669; Gstm1
chr3:107,814,027-107,821,968; Gfap chr11:102,746,534-102,760,963.
(B) Scatter plots comparing FPKMof TRAP-seq of an individual cell type (y axis, blue [left]; PCs, orange [center] GCs, green [right], BG) versus the averaged values
of the other two (x axis). Marked dots in each panel represent genes enriched in each cell type (PC blue, GC orange, and BG green) as previously described by
microarray analysis in the literature. Genes in bold indicate the reporter gene of each cell type (n = 4 per cell type).
(C) Gene distribution showing enrichment (y axis; Log2 FC, fold change) and expression values (Log2 FPKM) of enriched genes (>2 FC) of each cell type compared
individually with the other two, and averaged. The number of genes represented are indicated on the top left corner. Intensity of the color represents the level of
enrichment. Gray bars delimit genes that are highly enriched (horizontal, cutoff: 15-fold) and medium to highly expressed (vertical, cutoff: 6 FPKM).
(legend continued on next page)
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methyl-CpG-binding protein 2 (MeCP2) as the major 5hmC-
binding protein in the brain, and show that the R133C mutation
present in some Rett syndrome (RTT) patients preferentially
impacts 5hmC binding. Loss of MeCP2 does not alter the
genomic distribution of 5hmC, although the preferential nuclease
sensitivity of 5hmC containing chromatin is no longer present
in the absence of MeCP2. Our data support a model in which
MeCP2 binding to 5hmC can facilitate transcription in neural
cell types while at the same time acting in repression when
bound to 5mC containing DNA. Deciphering the relationships
between these functions and how they are used in specific
cell types will be essential for understanding the pathophysi-
ology of RTT.
RESULTS
TRAP-Seq Profiling of Gene Expression in PCs, GCs,
and BG
We have previously employed the translating ribosome affinity
purification (TRAP) method to determine that each of these
cell types expresses a unique complement of cell-specific
gene products (Doyle et al., 2008; Heiman et al., 2008).
Although these microarray data might suffice for comparative
analysis of gene expression and cytosine modification status,
we sought to improve our analysis by collecting gene expres-
sion data from these cell types using the more comprehensive
and quantitative high-throughput sequencing (HTS) of TRAP-
isolated mRNA (referred to hereafter as TRAP-seq). Data sets
for PCs, GCs, and BGs and their input tissue (whole cerebellum)
were generated in four biological replicates for each cell type,
resulting in an average 76.53 106 reads per sample (Figure S1A
available online). In total we obtained 1.36 3 109 mapped
reads, enabling deep analysis of the expressed genes in each
of these neural cell types (Figure S1). Principal component
and hierarchical clustering algorithms demonstrated the repro-
ducibility of TRAP-seq data between the replicas and genders
(Figures S1C and S1D). The quality of the TRAP-seq data
sets collected from PCs, GCs, and BG is further supported by
the fact that the correlation coefficients between data sets ob-
tained from a single cell type were between 0.94 and 0.99
(Figure S1B).
Inspection of TRAP-seq data from individual, well-known
genes illustrates the importance of cell-type-specific analysis
for the evaluation of gene expression (Table S1A). Alignment of
RNA-seq data collected from the whole cerebellum (Figure 1A,
bottom, black traces) demonstrates that each of the six genes
represented is expressed at detectable levels in the cerebellum,
and that differences in their expression levels are evident even by
visual inspection of the aligned data. However, it is apparent
from the top three traces that display the levels of expression
of these genes in PCs (blue), GCs (orange), and BGs (green)
that cell-specific expression levels cannot be evaluated in(D) Venn diagram of the 250 most expressed genes of each cell type.
(E) GO analysis of the 94most expressed genes in PC that are not highly expresse
of genes that are included in each term. GO terms that explain the main biologic
See also Figure S1.
Cwhole-tissue RNA-seq data. For example, both Pcp4 and
Gstm1 mRNAs are present at quite low levels in cerebellar
mRNA preparations, yet they are among the most abundantly
expressed genes in cells in which they are specifically
expressed. In contrast, the relationship between the GC-specific
mRNAs in total cerebellar samples and GCs TRAP-seq data is
much more robust because of their abundance in the
cerebellum.
To identify those genes that are differentially expressed
among PCs, GCs, and BG, TRAP-seq data collected from
each individual cell type was compared to the summed TRAP-
seq data from the remaining two cell types (Figure 1B; Table
S2A). These data were consistent with our previously collected
TRAP microarray data (Doyle et al., 2008), as shown by the
enrichment of positive control genes from each cell type in the
corresponding TRAP samples. However, the quantitative nature
of HTS relative to microarrays is readily apparent from the
improved linear range of the TRAP-seq analysis, as illustrated
by the significant enrichment of cell-specific mRNAs throughout
the range of expression, including those that occur at low levels
(for example Pou2af and Fgf7 in PCs) and those in very high
abundance (for example Pcp4 and Car8 in PCs) (Figure 1B).
Given the quantitative nature of HTS, and the fact that TRAP-
seq data measures those mRNAs that are engaged by the
ribosome and actively involved in protein synthesis, we were
interested in determining the biosynthetic signatures of these
very different cell types. Analysis of the TRAP-seq data generally
confirms the conclusion reached previously that each of these
cell types is characterized by the enriched expression of a large
set of genes (Figure 1C) (Doyle et al., 2008; Heiman et al., 2008).
However, comparison of the cell-specific enrichment of these
products and their absolute values of expression levels leads
to an additional interesting insight. In each of these cell types,
significant fractions of the most actively translated mRNAs are
cell-type-specific (Figures 1C and 1D). Furthermore, analysis of
the Gene Ontology (GO) terms for these highly expressed and
cell-specific transcripts yields a biochemical signature of each
cell type. For example, in PCs, 94 of the 250 mostly highly
expressed mRNAs are not expressed in either GCs or BG (Fig-
ure 1D). The GOs covered by these transcripts clearly reflect
the fact that PCs have a very large dendritic arbor and make
hundreds of thousands of synapses with GCs (Figure 1E). GO
categories revealed in this analysis for GCs and BG also reflect
their main functions: axonal maintenance and neuronal support,
respectively (Figure S1E).
5hmC Is Enriched in Euchromatin and 5mC in
Heterochromatin in Cerebellar Cell Types
To gain an initial appreciation of the relative distribution of 5hmC,
5mC, and chromatin domains in the distinctive nuclei of PCs,
GCs, and BG, immunofluorescence studies of eGFP/L10a bac-
TRAP transgenic mice were conducted (Figure 2). As previouslyd in GCs or BG as shown in (D), with a p cut off 0.05. In parenthesis, percentage
al features of PCs are highlighted in blue.
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Figure 2. 5hmC Is Enriched in Euchromatin
in Mature Cerebellar Cells
(A–C) Immunohistochemistry in cerebellar
sections showing the distribution of 5hmC and
5mC. Upper panels: Confocal microscopy image
of the granule cell layer of the cerebellum from
a Pcp2 bacTRAP (+/) (A), Neurod1 bacTRAP
(+/) (B), and Sept4 bacTRAP (+/) (C) expressed
in PCs, GCs, and BG, respectively. GFP expres-
sion (green), and immunostaining for 5hmC (red)
and 5mC (cyan), are shown. Scale bar is 50 mm.
Lower panels: Magnification of these areas de-
limited by dotted rectangles in (A), (B), and (C),
respectively. In the first three panels, DAPI staining
in blue is shown. Scale bar is 10 mm.
See also Figure S2.reported (Doyle et al., 2008; Kriaucionis and Heintz, 2009), each
of these cell types is readily visualized by the high levels of fluo-
rescence present on translating polysomes in the cell soma.
5hmC is distributed throughout the nucleoplasm of all three
cell types, and its distribution is clearly different from either
5mC or DAPI. 5hmC staining is evident in a dappled pattern
that nearly fills the PC nucleus, yet is excluded from both the
nucleolus and the adjacent, DAPI-bright heterochromatic caps
(Figure 2A, lower panels). Although the fraction of chromatin
stained with 5mC and/or DAPI in both GCs (Figure 2B, lower
panels) and BG (Figure 2C, lower panels) is evidently increased,1420 Cell 151, 1417–1430, December 21, 2012 ª2012 Elsevier Inc.the exclusion of 5hmC from nuclear
domains with very high 5mC content or
bright DAPI staining is maintained.
Cell-Type-Specific Utilization of
5hmC and 5mC in the Nervous
System
Given the distinctive structure of chro-
matin in PCs, GCs, and BG, and the large
number of gene products that are charac-
teristic of each of these cell types, we
were next interested in determining
whether the relationships between cyto-
sine modification status and the rate
and specificity of gene expression are
cell type specific. Accordingly, genomic
DNA for each cell type was obtained by
fluorescence activated cell sorting
(FACS) of eGFP/L10a labeled nuclei
from bacTRAP transgenic lines as previ-
ously described (Kriaucionis and Heintz,
2009). Genome-wide enrichment of
5hmC containing DNA fragments was
done using a selective chemical labeling
strategy (Song et al., 2011); 5mC was
enriched using methylated DNA immuno-
precipitation (MeDIP) (Jin et al., 2010;
Weber et al., 2005) followed by se-
quencing using Illumina platform. Two
biological replicas were done for eachcell type and DNA modification, resulting the total of 198 3 106
uniquely mapped reads. 33 3106 reads per condition provided
enough coverage to achieve correlation of 0.90 between two
halves of the sample, with estimated correlation of 0.95 per
sample (Figure S2A).
The chromosomal content of these epigenetic marks in each
cell type was unremarkable, except for the low 5hmC levels in
the X chromosome, as previously reported (Szulwach et al.,
2011) (Figure S2C). In general, the distribution of 5hmC across
the genome in these cell types was consistent with previous
studies of brain tissue (Figure S2B) (Song et al., 2011; Szulwach
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Figure 3. The Relationship between Cyto-
sine Methylation Status and Gene Expres-
sion Levels Is Cell Specific
(A) Metagene profiles of 5hmC and 5mC. Each line
represents percentage of genes ranked according
the expression levels.
(B) Genes were ranked by expression and grouped
in deciles (from 1 [higher] to 10 [lower]). FPKM of
gene expression and their correspondent FPKM of
5hmC, 5mC, and the ratio between the two,
averaged from single genes, are shown per cell
type. Last column of 5hmC and 5mC histograms
show averaged FPKMvalues of nonexpressed (ne)
genes. Pearson correlation coefficient (r) between
expression and feature and p values are shown.
(C) Representative examples of individual genes
and their values of 5hmC, 5mC, and gene
expression from the three cell types. Left panel
shows Pcp4, enriched in PCs. Middle panel shows
Etv1, enriched in GCs. Right panel shows Gfap,
enriched in BG. In each panel, values from PCs are
colored in blue, GCs in orange, and BG in green.
First row of each group indicates 5hmC normal-
ized values, and second row shows 5mC values.
Below, TRAP-seq normalized values are shown
per each cell type. The last row in black represents
the gene bodies located in this particular region of
the genome.
See also Figure S3.et al., 2011). Thus, 5hmC is preferentially enriched over the entire
transcription unit of expressed genes, and depleted from both
the TSS and intergenic regions (Figure S2D). Several additional
general features are revealed if gene body 5hmC and 5mC are
plotted relative to expression level in each of these cell types
(Figure S2D). First, the patterns of 5hmC and 5mC are clearly
complementary. Second, for highly expressed genes, it appears
that 5mC is depleted over the gene bodies. Third, the levels of
5hmC enrichment and 5mC depletion vary between cell types.Cell 151, 1417–1430, DeTo interrogate further the relationships
between gene expression and cytosine
modification status in each cell type,
genes were subdivided into groups
based on the cell-specific expression
rank, and plotted against metagene
centric features (Figure 3A). These plots
confirmed the depletion of 5hmC at the
TSS, and identified a characteristic peak
of 5hmC just 900 bp 50 of the TSS that
showed no correlation with the expres-
sion state of the genes. Genes in the high-
est expression percentiles tend to have
more 5hmC and less 5mC over their
gene bodies than ones in the lowest
expression percentiles, when 5hmC and
5mC levels in the gene body reach the
genome average and 5mC drops below
(Figure 3A; Table S1A). However, that
these relationships vary significantly
between cell types becomes readilyapparent when calculating correlations between expression
and cytosine modification for each cell type (Figure 3B). For
example, inspection of the 5hmC and 5mC histograms for
deciles of genes ranked on expression demonstrates that for
GCs, there are highly significant relationships among gene ex-
pression, elevated 5hmC levels (Pearson correlation, r = 0.692;
p = 0.013), and depleted 5mC levels (r = 0.776; p = 4.1 3 103)
within the gene body. Significant relationships of this type are
also evident in the BG data sets (5hmC r = 0.660, p = 0.018;cember 21, 2012 ª2012 Elsevier Inc. 1421
5mC r = 0.758, p = 5.4 3 103). However, while a clear relation-
ship between gene expression and 5mC depletion is evident in
PCs (r = 0.689; p = 0.013), the relationship between elevated
gene body 5hmC and gene expression is much less clear (r =
0.526; p = 0.059). Next, we considered the possibility that it is
the ratio of 5hmC to 5mCwithin the gene body that is most infor-
mative with regard to gene expression. Support for this idea
comes from the fact that in all cell types, the r coefficients are
highly significant and increased if calculated on the basis of
the 5hmC/5mC ratio (PC, r = 0.867; GC, r = 0.857; BG, r =
0.799). An inverse correlation between abundance of 5mC and
5hmC over gene bodies is indicated by the fact that the 5hmC/
5mC ratio had the best correlation with gene expression (Fig-
ure 3B). This is expected because hydroxylation of 5mC results
in 5hmC (Tahiliani et al., 2009), and both of these marks cannot
exist on one base. However, it was surprising to see the deple-
tion of 5mC signal correlating better with gene expression than
presence of 5hmC, which is especially obvious in PCs (Figures
3A and 3B). We considered the possibility that the low 5mC
signal in addition to the evident increase of 5hmC could indicate
the presence of unmodified C, 5-formylC (5fC) or 5-carboxylC
(5caC). Because 5fC and 5caC levels are too low to be confi-
dently detected in the whole brain (data not shown and Ito
et al., 2011), we reasoned that some sites may have cell-type-
specific gain of unmodified Cswithin potential modification sites.
Bisulfite sequencing of selected loci demonstrated the increase
of unmodified CpGs within the regions displaying cell-type-
specific decrease of 5mC signal (Figure S3A). The unmodified
CpGs ranged from 91% in Diras2 gene to 53% in Foxp4 gene
in a cell type showing a low 5mC signal, and 0% to 3% (respec-
tively) in a cell type with high 5mC signal (Figure S3A). These
results illustrate the fact that both the loss of cytosine modifica-
tion at the specific CpG residues and the accumulation of 5hmC
within the gene body can contribute substantially to expression.
Cell-type-specific relationships between cytosine methylation
status and gene expression are also apparent when examining
the distributions of 5hmC and 5mC in individual highly expressed
genes (Figures 3C and S3B; Table S1A). For example, from
inspection of the Pcp4 locus, it is evident that this gene is ex-
pressed at elevated levels in PCs and that the Pcp4 gene body
is depleted in 5mC specifically in PCs, but that the level of
5hmC within the Pcp4 gene does not vary visibly between cell
types. In contrast, in GCs and BG, many genes that are ex-
pressed at elevated levels display both significant enrichment
of 5hmC within the gene body, and modest depletion of 5mC
(e.g., Etv1, Gfap). Strikingly, we have observed individual
instances where a differentially modified region predicted the
presence of a transcribed gene that is present only in the most
recent annotations of the genome. These data clearly illustrate
a strong and cell-type-specific relationship between cytosine
modification status and gene expression for individual genes.
MeCP2 Is an Abundant 5mC and 5hmC-Binding Protein
in the Mouse Brain
The enrichment of 5hmC and the depletion of 5mC throughout
the bodies of expressed genes in terminally differentiated neural
cell types, and the fact that 5hmC is at least ten timesmore abun-
dant in neurons that in ES cells, suggests that the proteins de-1422 Cell 151, 1417–1430, December 21, 2012 ª2012 Elsevier Inc.coding epigenetic information in the brain may be different
from those present in ES cells. To identify these factors, nuclear
extracts prepared from rodent brain (Klose and Bird, 2004) were
incubated with magnetic beads coated with DNA containing
unmodified C, 5mC, or 5hmC DNA in the presence of excess
of nonspecific DNA competitor, followed by isolation of the
beads and visualization of proteins after elution and SDS-
PAGE. As shown in Figure 4A, these experiments revealed
a band of 70 kDa that was pulled down with both 5mC and
5hmC, but was not present in the proteins eluted from beads
coated with DNA containing unmodified C. This band was
excised from a preparative gel of this type, and the protein was
identified by mass spectroscopy as MeCP2 (Figure S4A). To
confirm this result, similar affinity purifications were repeated
from brain nuclear extracts of wild-type (WT) and Mecp2
knockout (KO) animals using beads coated with DNA containing
C or 5hmC, and assayed using Southwestern analysis (Campoy
et al., 1995). Thus, membrane-bound renatured proteins were
probed with 32P-labeled DNA containing either 5mC (Figure 4B,
left panel) or 5hmC (right panel), revealing a protein of the correct
molecular weight that can bind both 5mC-containing and 5hmC-
containing probe DNAs, and that is not present in samples
prepared from KO animals. To our surprise, no other protein
with high specificity for 5hmC DNA was revealed in these
studies, even in the absence of MeCP2.
Recombinant Human MeCP2 Binds 5mC and 5hmC
In Vitro
The identification of MeCP2 as a major 5hmC-binding protein
in rodent brain is surprising given previous in vitro studies report-
ing that it binds 5mC-containing DNA much more avidly than
5hmC-containing DNA (Bostick et al., 2007; Valinluck et al.,
2004). To address this issue directly, an N-terminal (NT) fragment
of human MeCP2 containing its methyl-CpG-binding domain
(MBD) (residues 1–205) was produced in E. coli, and used in
electrophoretic mobility shift assays (EMSA) to measure binding
to 5mC, 5hmC, or unmodified DNA. At all concentrations tested,
the MeCP2 NT failed to bind the unmodified probe, while avidly
binding both the 5mC and 5hmC probes (Figure 4C). As an
additional control, EMSA probes were reacted with T-4 phage
b-glucosyltransferase (bGT) and uridine diphosphoglucose
(UDP-glucose), which results in the specific glucosylation of
5hmC-containing DNA without affecting 5mC-containing and
C-containing probes (Szwagierczak et al., 2010). Binding prop-
erties of other MBD family proteins (Figure 4D) were also
analyzed. MeCP2 NT bound specifically to unreacted 5mC and
5hmC probes. Glucosylation of 5hmC probe blocked binding,
whereas binding to the 5mC probe was retained as 5mC is
refractive to glucosylation. MeCP2 binding to 5hmC was not
sequence specific because the binding properties of MeCP2 to
a variety of probes selected from the mouse genome did not
vary significantly (Figure S4C). In contrast, MBD1, 2, and 4 all
bound strongly to 5mC-containing DNA, and did not bind avidly
to 5hmC-containing probes. As previously reported (Yildirim
et al., 2011), weak and glucosylation-sensitive binding of
MBD3 was observed to both 5mC and 5hmC DNAs, and the
mobility of the MBD3/5hmC complex was slightly retarded rela-
tive to the MBD3/5mC complex.
Figure 4. MeCP2 Is the Major Protein that
Binds 5hmC
(A) Silver-stained SDS-PAGE gel of nuclear
proteins from frozen rat cerebella that bound
beads coated with unmodified C, 5mC, or 5hmC
DNA. Arrow pointing at the band that was excised
and identified by MS from a Coomassie-stained
replica gel.
(B) Southwestern blot of the nuclear proteins from
cerebella ofWT or KOmice (IN) that bound to C- or
5hmC-coated beads probed with radioactive 5mC
or 5hmC DNA.
(C) EMSA of C, 5mC (M), or 5hmC (H) probes with
increasing concentrations (0–2 pmol) of recombi-
nant human MeCP2. The arrow points at the
MeCP2-dependent low-mobility complexes.
(D) EMSA of C, 5mC (M), and 5hmC (H) probes in
presence of 1 pmol MeCP2 (aa 1–205), 1.2 pmol
MBD1, 0.5 pmol MBD2, 50 pmol MBD3, or 2.5
pmol MBD4. Probes reacted with bGT prior to
labeling are indicated (+). Arrows point at protein-
dependent DNA complexes.
See also Figure S4.R133C, an MeCP2 Residue Mutated in Rett Syndrome,
Alters Preferentially Binding to 5hmC DNA
If binding of MeCP2 to 5hmC is critical for its role in the regulation
of neuronal nuclear function and gene expression, then it is
possible that a subset of the MECP2 mutations that cause RTT
disrupt 5hmC binding without strongly impacting 5mC interac-
tion. To determine if this is the case, binding of MeCP2 MBDs
(amino acids [aa] 1–205) carrying a variety of previously charac-
terized RTT mutations were assayed (Kudo et al., 2003). To
represent two extreme cases of DNA binding activity, three
mutations were selected: D121G, which abolishes 5mC binding,
and L100V and A140V, which don’t disrupt 5mC binding. The
rest of the RTT-causing mutations in the MBD were chosenCell 151, 1417–1430, Debecause they showed no or little disrup-
tion of nuclear localization or 5mC bind-
ing. Although the general effect of these
mutations was to inhibit binding to both
5mC and 5hmC, we observed a pro-
nounced decrease in the interaction with
5hmC relative to 5mC DNA with the
MeCP2 NT carrying the R133C substitu-
tion (Figure 5A). To provide independent
analytical data to support the conclusions
of the EMSA assays presented above,
surface plasmon resonance (SPR) assays
were used to measure the binding of full-
length MeCP2, the MeCP2 NT, other
MBD proteins, and the MeCP2-carrying
R133C mutation. 50-biotinylated C, 5mC,
or 5hmC probes were immobilized on
parallel flow cells (Fc) of a streptavidin-
coated sensor chip to their saturation
level. The steady-state SPR response of
each Fc at serial dilutions of above-
mentioned proteins is shown in Figure 5B.As predicted,MeCP2 (bothNT and full length, Figure 5B) showed
specific binding to both 5mC-containing and 5hmC-containing
DNA that was strongly dependent on protein concentration,
whereas binding to C-containing DNA plateaued at very low
protein concentrations, consistent with nonspecific binding. In
contrast, MBD2 bound strongly to 5mC-containing probes and
showed nonspecific binding to both C and 5hmC. Interestingly,
binding characteristics of the MeCP2 R133C mutant to 5hmC
was similar to those of nonspecific binding.
To further assess these results, themaximumbinding capacity
(Bmax) of each protein was calculated for each probe from
steady-state binding curves (Figures 5C and S5A). As expected,
MBD1, 2, and 4 showed highly significant specific binding tocember 21, 2012 ª2012 Elsevier Inc. 1423
AB
C
Figure 5. R133C Mutation of MeCP2 Prefer-
entially Disrupts Its Binding to 5hmC
(A) The EMSA showing 5hmC binding character-
istics of several MeCP2 point mutations (0.5 [13]
or 1 [23] pmol) observed in RTT patients. Arrow
shows the expected position of theMeCP2-
dependent complexes.
(B) Steady-state binding curves of MeCP2 (aa
1–205), MBD2, MeCP2, and MeCP2 R133C to C,
5mC, and 5hmC reported as SPR response of Fcs
immobilized with indicated probes upon applica-
tion of serial dilutions of proteins. MeCP2 binding
to both 5mC and 5hmC (upper left panel) shows
specificity. MBD2 is chosen to represent the
characteristic curve of 5mC specificity (upper right
panel). Full-length MeCP2 also binds 5hmC and
5mC with similar affinities, and R133C mutation of
MeCP2 shows nonspecific binding to 5hmC. SE is
shown.
(C) The extracted Bmax values, normalized for the
protein mass, of MBD family of proteins, MeCP2
(1–205), full-length MeCP2, and R133C mutants
(n = 4, SD; ****p < 0.0001; ***p < 0.001; **p < 0.01;
*p < 0.05 in F test to compare variances). SEM is
shown.
See also Figure S5.5mC DNA. Both the MeCP2 MBD and the full-length protein
bound 5mC and 5hmC specifically, consistent with the pull-
down experiments, the Southwestern results, and the EMSA
data presented above (Figures 4, 5, and S5). No significant differ-
ence was observed in the Bmax of MeCP2 binding to 5mC and
5hmC. The most interesting and unexpected data revealed by
these SPR assays (Figures 5 and S5) is that R133C MeCP2
mutant retained most of its 5mC binding capability (mean
Bmax = 76% of WT, p = 0.77) despite loss of specific binding
to 5hmC (mean Bmax = 25% of WT, p = 0.0029) (Figure S5).
The fact that this single substitution in the MeCP2 MBD can
strongly and preferentially impact the substrate binding proper-
ties of MeCP2 is important, because identification of MeCP2
mutations that retain WT 5mC binding in the R133C variant yet
retain severely diminished 5hmC binding can provide an impor-
tant avenue for assessing the role of MeCP2 binding to 5hmC in
the pathophysiology of RTT. Furthermore, these data demon-
strate that small changes the structure of MeCP2 may influence
its relative binding properties to 5mCand 5hmC, raising the inter-
esting possibility that the posttranslational modifications to
MeCP2 that have been shown to occur in response to a variety1424 Cell 151, 1417–1430, December 21, 2012 ª2012 Elsevier Inc.of stimuli (Chen et al., 2003; Tao and
Wu, 2009; Rutlin and Nelson, 2011;
Adkins and Georgel, 2011; Gonzales
et al., 2012) could alter its substrate
specificity and downstream functions.
The Distribution of Genomic 5hmC
Does Not Change in Mecp2
Knockout Neurons
Given the demonstration that MeCP2
binds strongly to 5hmC-containing DNA,and the strong positive correlation between gene body 5hmC
levels and gene expression observed in GCs, it was of interest
to determine whether the MeCP2 helps to establish the levels
of 5hmC in expressed genes, or whether 5hmC acts upstream
of MeCP2 in its relationship to gene expression. To investigate
this issue, the distribution of 5hmC in GC genomes purified
from WT and KO mice was mapped and its relationship to
gene expression analyzed. Inspection of these data reveals no
significant differences in the distribution of 5hmC as a result of
loss of MeCP2 (Figures 6A and 6B). Consequently, the strong
positive correlation between GC gene expression and 5hmC
gene body content (r = 0.692, p = 0.13) is maintained in the
absence of MeCP2 (r = 0.730, p = 0.008) (Figure 6C; Table
S1C). We note, however, that a small but significant decrease
in gene body 5hmC levels was evident for expressed genes
across all deciles in the MeCP2 KO granule cells (Figures 6C
and S6B). To determine whether this reflected active transcrip-
tion, we also analyzed the levels of gene body 5hmC in nonex-
pressed genes in the knockout animals. Again, in the KO granule
cells, a significant, small difference in 5hmC levels was
observed. Although we do not know the origin of this finding,
Figure 6. 5hmCLevels over GeneBodies Do
Not Change in Mecp2 KO
(A) Heatmap of 5hmC FPKM over the chromo-
somes. Both replicas from wild-type (WT) and
Mecp2 null (KO) animals are shown.
(B) Chromosome 10 showing the levels of 5hmC
and RNA-seq in WT and KO animals.
(C) Genes were ranked by expression and group-
ed in deciles. FPKM of gene expression in GC, and
their correspondent FPKM of 5hmC in the GCWT,
in the GC KO and the average fold change (FC) of
each decile are shown. Pearson correlation coef-
ficient (r) between expression and feature and p
values are shown (*p < 0.05).
(D) Venn diagram of the dysregulated genes in KO.
A total of 36 genes from the upregulated genes are
expressed in GCs, 3 of which are enriched (>2 FC)
over PCs and BG. A total of 268 genes are
downregulated and expressed in GC, 24 of which
are enriched (>2 FC) over PCs and BG.
(E) Box and whisker plots of 5hmC and 5mC levels
of the 24 downregulated genes enriched in GCs
(left panel) and 5hmC in WT and KO GCs (right
panel). Wilcoxon signed-rank test coefficient (z)
and p values are shown (*p < 0.05).
(F) Average of expression of the 24 downregulated
genes enriched in GCs and three upregulated
genes enriched in GCs (*p < 0.05 in t test). Data are
shown as SE.
(G) Examples of dysregulated genes in the KO and
enriched inGCs.5hmC,5mC, andgeneexpression
values are represented. Left panel shows Cgnl1 in
red upregulated in KO (RNA-seq values from WT
in black andKO in gray). Right panel showsNdufa5
in green downregulated in KO. In each panel,
values fromPCsarecolored in blue,GCs in orange,
and BG in green. The first line of each panel indi-
cates GC WT 5hmC, the second line indicates GC
KO 5hmC, and the third line indicates 5mC. Below,
TRAP-seq are shown for each cell type.
See also Figure S6.the fact that it is occurring in genes irrespective of their expres-
sion levels argues strongly that it is not the result of transcrip-
tional activity.
To identify genes whose expression is altered in KO GCs, and
determine whether the cytosine modification status of this class
isalteredasa resultof lossofMeCP2,RNA-seqdatawascollected
fromcerebella ofWT andKOanimals (Table S1B). Consistentwith
previous results (Ben-Shachar et al., 2009), the majority of genes
whose expression is altered in the cerebellum in response to
loss of MeCP2 were downregulated (Figure 6D; Tables S2C and
S2D). To determinewhether genomic 5hmC levels changedwithin
this class of genes in the KO, we restricted our analysis to the 24Cell 151, 1417–1430, Degenes that are expressed preferentially in
GCs because of the cell-type-specific
relationships between expression and
cytosinemodification documented above.
LossofMeCP2hadnoeffecton the level or
distribution of GC gene body 5hmC for
these genes (Figures 6E and 6G). As ex-pected, this class of genes was expressed at significantly higher
levels than the few upregulated genes identified in the RNA-seq
experiments, and they were enriched in 5hmC and depleted in
5mC (Figures 6E–6G). We conclude, based on these data, that
the distribution of 5hmC is determined by mechanisms that are
independent of MeCP2, and that 5hmC must act upstream of
MeCP2 to facilitate transcription.
5hmC, MeCP2, and the Organization of Neuronal
Chromatin
Evidence from a wide variety of studies supports a general
model in which MeCP2 binding to 5mC at CpG dinucleotidescember 21, 2012 ª2012 Elsevier Inc. 1425
throughout the genome plays an important role in transcriptional
repression (Guy et al., 2011). However, the observations that in
brain nuclei a large fraction of MeCP2 is localized within highly
nuclease accessible regions (Thambirajah et al., 2012), that
loss of MeCP2 can lead to downregulation of expressed genes
(Ben-Shachar et al., 2009; this study), and that 5hmC is enriched
in the gene bodies of highly expressed genes (Song et al., 2011;
this study) suggests that MeCP2 binding to 5hmC may also
play a role in facilitating gene expression. If this is the case,
expressed genes that have a high 5hmC/5mC should be en-
riched in highly accessible chromatin. To test this prediction,
we first measured the relationship between chromatin accessi-
bility and cytosine modification status in the cerebellar nuclei
(Figures 7A and S7). Nuclei were isolated and treated with
increasing concentrations of micrococcal nuclease (MNase).
We observed that genes with high 5hmC/5mC values were lost
from nuclei at low MNase concentrations, indicating their pres-
ence in accessible chromatin. Genes resistant to low concentra-
tions of MNasewere preferentially enriched in 5mC and depleted
in 5hmC (Figure S7B). As expected, genes that are not ex-
pressed and have high levels of 5mC were resistant to MNase
digestion.
Given the high abundance of MeCP2 in the brain (Figure S4B)
(Guy et al., 2001; Skene et al., 2010; Thambirajah et al., 2012),
andourdemonstration thatMeCP2bindsavidly to 5hmCcontain-
ingDNA in vitro, wewere next interested in assessing its potential
role in global regulation of chromatin accessibility. To do so,
cerebellar nuclei were isolated from 5-week-old WT and KO
mice (Guy et al., 2001). For each sample, a time course of MNase
digestion was performed, and the release of 5hmC- and 5mC-
enriched DNA was assayed with antibodies against 5mC and
5hmC on a Southern blot (Figures 7B and 7C). The signal from
the high-molecular-weight, nuclease-resistant fraction was
measured in four independent cohorts of WT and KO mice, its
percentage was calculated to total signal in the lane, and the
data at each time of digestion plotted (Figures 7B and 7C). Two
interesting results were obtained. First, we observed that
5hmC-enriched DNA is released readily from chromatin by
MNase digestion, whereas 5mC-containing chromatin is signifi-
cantly more resistant to digestion (Figure 7C). This is consistent
with the analysis of individual genes shown in Figure 7A, and
confirms previous studies demonstrating that the 5mC-enriched
DNA is present MNase-resistant compact structures (Karymov
et al., 2001). Second, in KO mice, a significant small delay in
digestion of 5hmC-containing DNA was observed, whereas no
reproducible difference in the sensitivity of 5mC-containing
DNA to MNase was evident (Figures 7B and 7C). These
data demonstrate that MeCP2 regulates the accessibility of
5hmC-containing DNA to MNase, supporting a model in which
MeCP2binding to5hmCwithin highly expressedgenesmay facil-
itate transcription through its effects on chromatin organization.
DISCUSSION
The data presented here identify a role for MeCP2 in the regula-
tion of chromatin structure, and support a model for the organi-
zation of chromatin and gene expression that is of particular
importance for CNS. Thismodel depends on threemajor factors:1426 Cell 151, 1417–1430, December 21, 2012 ª2012 Elsevier Inc.depletion of 5mC within the bodies of expressed genes, accu-
mulation of high levels of 5hmC within these gene bodies, and
occupation of 5hmC-binding sites by the abundant and CNS-
enriched protein MeCP2. The contributions of each of these
factors to gene expression vary between cell types, suggesting
that each of them can be regulated independently. Based on
our data, and the fact that both 5hmC and MeCP2 are at least
an order of magnitude more abundant in CNS than in the
periphery (Kriaucionis and Heintz, 2009; Skene et al., 2010), we
propose that binding of 5hmC by MeCP2 plays a central role in
the epigenetic regulation of neural chromatin and gene expres-
sion. Advances in our understanding of the pathophysiology of
RTT will require further investigation of this new role for MeCP2
in facilitating gene expression when bound to 5hmC in the
context of the traditional repressive functions it elicits upon its
binding to 5mC (Guy et al., 2011).
Although a mechanism by which MeCP2 binding to 5hmC
could regulate chromatin accessibility remains to be determined,
several inferences can be drawn from the existing data. First, the
distribution of 5hmC throughout the transcription unit of highly
expressed genes distinguishes this mechanism from the estab-
lished roles of MeCP2 and other MBD family proteins in the orga-
nization of repressive chromatin complexes at promoters and
enhancers (Guy et al., 2011; Yildirim et al., 2011). Our data
support the idea that the action of MeCP2 is more akin to a linker
histone (Skene et al., 2010), occupying expressed genes through
its binding to 5hmC. They are also consistent with the observa-
tions that MeCP2 stably associates with nucleosomes (Chandler
et al., 1999), that it can compete with histone H1 for nucleosome-
binding sites (Ghosh et al., 2010), and that the levels of MeCP2
and histone H1 are inversely correlated in neurons (Skene et al.,
2010). However, our observations that MeCP2 binds with high
affinity to 5hmC and that 5hmC is enriched in expressed genes
that are nuclease sensitive forces a reevaluation of the role
of MeCP2 binding to chromatin in neural cell types. We propose
that binding of MeCP2 to 5hmC in expressed genes facilitates
transcription through organization of dynamic chromatin
domains. This model provides a mechanistic explanation for the
recent demonstration thatMeCP2can also activate gene expres-
sion, as somegenesarebothdownregulatedupon lossofMeCP2
and upregulated in mice with increased Mecp2 gene dosage
(Ben-Shachar et al., 2009; Chahrour et al., 2008; Figure 6).
Second, our data suggest that both depletion of gene body
5mC and MeCP2 binding to 5hmC are important to establish
chromatin domains that facilitate transcription. Thus, there is
a strong inverse correlation between gene expression and gene
body 5mC. It seemsprobable that this reflects both the biochem-
ical nature of 5mC binding by MBD proteins, and the conse-
quences of their action. For example, it has recently been shown
that two populations of MeCP2 are present in the brain: one in
chromatin regions that are enriched in nucleosomes, and the
other that is loosely bound to highly accessible chromatin
domains (Thambirajah et al., 2012). Given our demonstration
that genes enriched in 5hmC are also preferentially present in
these MNase sensitive domains, it seems likely that this loosely
bound MeCP2 is associated with 5hmC rather than 5mC. This
suggests that the interaction of MeCP2 with 5hmC establishes
a dynamic state of chromatin that would be quite sensitive over
Figure 7. 5hmC and MeCP2 and the Organization of Neuronal Chromatin
(A) Nuclei were digested with MNase for 5 min and analyzed by quantitative PCR. The correlation between the chromatin accessibility of individual genes and
expression in 5hmC, 5mC, and 5hmC/5mC (fourth panel) are shown (n = 3).
(B) Ethidium bromide (EtBr)-stained 2%agarose gel showing DNA fragments at different time points duringMNase digestion (1–32min) of nuclei from cerebella of
WT or KO mice. The blotted gel that was probed with 5hmC or 5mC antibodies.
(C) The mean of the percent intensity in high-molecular-weight DNA (HMW) in (B) was plotted as a function of time with SEM. Upper panels show the comparison
in 5hmC and 5mC in the WT (left panel) and in MeCP2 KO (right panel). Lower panels show the comparison betweenWT and MeCP2 KO in 5hmC and 5mC. *p <
0.05 in an unpaired t test.
See also Figure S7.time to the presence ofmuchmore stable complexes established
within that domain by binding of MeCP2 or other less abundant
MBD family proteins to 5mC (Lopez-Serra et al., 2006). A cell-Cspecific and dynamically regulated gene expression pattern
might be explained by a three-dimensional chromatin structure
established by regulating levels of 5mC, 5hmC, MeCP2, andell 151, 1417–1430, December 21, 2012 ª2012 Elsevier Inc. 1427
other MBD proteins. Changes in the level or activity of MeCP2
would disrupt this balance, resulting alterations in chromatin
structure and, consequently, gene expression. Because the
levels of 5hmC and 5mC and the proteins that bind them vary
in each cell type, the phenotypic consequences of changes in
the function of MeCP2, whether as a result of mutation (Adkins
and Georgel, 2011; Tao andWu, 2009; Amir et al., 1999) or post-
translational modification (Rutlin and Nelson, 2011; Gonzales
et al., 2012), will be cell type and circuit specific.
Third, our understanding of the pathophysiology of RTT must
now encompass the role of MeCP2 binding to 5mC in the repres-
sion of gene expression (Chahrour and Zoghbi, 2007), and our
present results supporting a model in which MeCP2 binds to
5hmC within active transcription units. For example, the obser-
vations that the distribution of 5hmC and 5mC and their relation-
ship to gene expression varies depending on cell type, and that
disease-causing mutations of MeCP2 can impact 5hmC binding
preferentially (e.g., R133C), could lead to important insights into
the specific phenotypes associated with altered MeCP2 func-
tion. Our data support previous genetic studies demonstrating
that the consequences of MeCP2 loss in different neural cell
types differ both quantitatively and qualitatively (Ben-Shachar
et al., 2009), and suggest that the specific biochemical proper-
ties of mutant MeCP2 proteins may inform our understanding
of their clinical consequences. For example, it is well docu-
mented that patients carrying the R133C mutation have a milder
form of RTT that is characterized by delayed onset regression,
with improved speech and motor skills (Bebbington et al.,
2008). However, for many other characteristics, including
breathing abnormalities, sleep problems, mood disturbances,
and epilepsy prevalence, no significant differences are evident
between patients bearing R133C or othermutations (Bebbington
et al., 2008). Does this mean that these latter clinical features of
RTT are associated with loss of its 5hmC binding capacity, and
that they reflect differences in the relative importance of 5hmC
versus 5mC binding in different cell types? Is it possible that
5hmC plays a role in the phenotypes that result in categorization
of RTT as an autism spectrum disorder? We cannot presently
answer these questions, although the generation of mouse
models with ‘‘improved’’ MeCP2 mutations that continue to
strongly impact 5hmC binding yet retain WT 5mC interaction
offers an important avenue toward investigation of these issues.
Finally, while we believe that binding of MeCP2 to 5hmC is
a major step in decoding 5hmC in the CNS, many issues remain
to be addressed. We have not, for example, assessed the influ-
ence of activity-dependent mechanisms (Cohen et al., 2011) on
the interactions of MeCP2 with 5mC-containing or 5hmC-con-
taining DNA. We have not yet had the opportunity to analyze
the relationships between gene expression, 5mC, and 5hmC
in other glial cell types that have been shown recently to play
important roles in mouse models of RTT (Derecki et al., 2012;
Lioy et al., 2011). We do not understand the relative importance
of the mechanism described here and the recent observation
that MBD3 can bind to 5hmC-containing DNA (confirmed
here), and that it is colocalized with Tet1 at 5hmC-containing
promoters in ES cells (Yildirim et al., 2011). And we do not
know if 5hmC-mediated demethylation plays a role in the
dynamic control of epigenetic regulation of specific CNS cell1428 Cell 151, 1417–1430, December 21, 2012 ª2012 Elsevier Inc.types (Cortellino et al., 2011; Ito et al., 2011). Investigation of
these and other issues in specific neuronal and glial cell types
will be essential if we are to decipher the role of 5hmC in CNS,
and understand its contributions to the pathophysiology of RTT.
EXPERIMENTAL PROCEDURES
TRAP-Seq
RNA from translating polysomes was extracted as previously described (Hei-
man et al., 2008) (see Extended Experimental Procedures). We obtained more
than 30million 50 bp single-end reads per sample (Figure S1A) that were sepa-
rately aligned to the mouse genome (mm9) downloaded from UCSC. TopHat
software (version 1.3.1) was used for processing reads. Segment size was
set to 25 bp with two mismatches to the reference allowed, and the minimum
anchor size was set to 10 bp with no mismatches allowed. The resulting
aligned data in bam format were assembled into transcripts using Avadis
NGS 1.3.0 (Strand Scientific Intelligence, San Francisco, CA, USA). Annotated
transcripts were obtained from Ensembl transcripts (2010.10.07; http://www.
ensembl.org). Transcript abundance was measured in fragments per kilobase
of exon per million fragments mapped (FPKM) similarly to RPKM used in (Mor-
tazavi et al., 2008). Finally, differentially expressed genes were identified by
performing a negative binomial test using the DESeq package (Anders and
Huber, 2010) of R/Bioconductor (Gentleman et al., 2004). Our conditions
were selected and qualitatively validated by comparing the differential expres-
sion results with in situ hybridization data from Allen Brain Atlas (see Extended
Experimental Procedures). RNA-seq from Mecp2 KO and WT cerebella was
done following the same protocol as inputs of TRAP-seq.
5hmC Pull-Down and MeDIP Sequencing
Sorted nuclei from the three cell types were manipulated in parallel during the
procedure. 5hmC was pulled down as described (Song et al., 2011; see
Extended Experimental Procedures). After purification, DNA was amplified
as described in TruSeq DNA Sample kit. MeDIP was done as described in
(Weber et al., 2005) with the indicated modifications. A total of 0.5–1 mg
DNA was used for each experiment. Sonicated DNA was end-repaired fol-
lowed by ligation to Illumina paired end sequencing adapters (Illumina,
PE-102-1003). Enrichment was done using anti-methyl C antibody (Eurogen-
tech, BI-MECY-0100), followed by amplification with Illumina primers and
size selection on an agarose gel. Input samples were produced for each cell
types in both procedures.
Both 5hmC- and 5mC-enriched DNA were then sequenced using Illumina
platform obtaining more than 50 3 106, 36 bp single-end reads per sample.
Reads were aligned to mm9 mouse genome assembly using Bowtie v0.12.7
(m1–best). Further analysis was done using Bioconductor v2.9 using pack-
ages chipseq, biomaRt, rtracklayer, MEDIPS, and custom scripts. Two biolog-
ical MeDIP-seq replicas were done for each of the cell type.
5hmC Affinity Pull-Down
A total of 1 mg 50-biotinylated C, 5mC, or 5hmC BDNF probe was immobilized
on Dynabeads M-280 Streptavidin (Invitrogen) following the manufacturer’s
recommendations. To pull down 5hmC-binding proteins from brain nuclear
extract, beads were incubated with 2mg nuclear extract (see Extended Exper-
imental Procedures). Isolated proteins were analyzed by mass spectrometry.
For more experimental details, please see the Extended Experimental
Procedures and Table S3.
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